XTX Topco Ltd Acquires 1,110 Shares of Penumbra, Inc. (NYSE:PEN)

XTX Topco Ltd increased its stake in Penumbra, Inc. (NYSE:PEN) by 70.7% during the third quarter, Holdings Channel.com reports. The firm owned 2,680 shares of the company’s stock after purchasing an additional 1,110 shares during the quarter. XTX Topco Ltd’s holdings in Penumbra were worth $521,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. True Wealth Design LLC purchased a new stake in Penumbra in the third quarter worth about $26,000. GAMMA Investing LLC increased its holdings in Penumbra by 111.1% in the 3rd quarter. GAMMA Investing LLC now owns 171 shares of the company’s stock worth $33,000 after acquiring an additional 90 shares in the last quarter. Park Place Capital Corp raised its stake in Penumbra by 1,473.9% during the 3rd quarter. Park Place Capital Corp now owns 362 shares of the company’s stock worth $70,000 after acquiring an additional 339 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Penumbra by 1,845.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 389 shares of the company’s stock valued at $70,000 after purchasing an additional 369 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its position in shares of Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after purchasing an additional 43 shares during the period. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Penumbra Price Performance

PEN stock opened at $245.71 on Friday. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $277.34. The firm has a market capitalization of $9.43 billion, a P/E ratio of 290.51, a price-to-earnings-growth ratio of 2.55 and a beta of 0.51. The company has a fifty day simple moving average of $226.32 and a two-hundred day simple moving average of $201.36. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.16. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The firm had revenue of $301.04 million during the quarter, compared to the consensus estimate of $297.36 million. During the same quarter last year, the firm earned $0.67 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts anticipate that Penumbra, Inc. will post 2.81 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In related news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $190.76, for a total value of $114,456.00. Following the completion of the sale, the executive vice president now directly owns 60,488 shares in the company, valued at $11,538,690.88. This trade represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Lambert Shiu sold 654 shares of Penumbra stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $243.01, for a total transaction of $158,928.54. Following the transaction, the chief accounting officer now directly owns 20,028 shares of the company’s stock, valued at $4,867,004.28. The trade was a 3.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,418 shares of company stock worth $10,624,973. 5.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on PEN. Stifel Nicolaus started coverage on shares of Penumbra in a research report on Tuesday, September 17th. They set a “buy” rating and a $238.00 price objective on the stock. Truist Financial boosted their price objective on Penumbra from $200.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Piper Sandler boosted their price target on Penumbra from $235.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, November 20th. Finally, Royal Bank of Canada increased their price objective on shares of Penumbra from $205.00 to $222.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $252.42.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.